4.7 Review

Modulating inflammation for cancer therapy

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 216, Issue 6, Pages 1234-1243

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20181739

Keywords

-

Funding

  1. Georg-Speyer-Haus
  2. LOEWE Center Frankfurt Cancer Institute - Hessen State Ministry for Higher Education, Research and the Arts [III L 5 - 519/03/03.001 - (0015)]
  3. Deutsche Forschungsgemeinschaft [FOR2438: Gr1916/11-1, SFB 815, SFB 1177, SFB 1292]
  4. German Federal Ministry of Health of the State of Hessen
  5. Ministry of Higher Education Research and the Arts of the State of Hessen

Ask authors/readers for more resources

A link between chronic inflammation and development of tumors is well established. Moreover, it has become evident that tumorigenesis is not a cell autonomous disease, and an inflammatory microenvironment is a prerequisite of basically all tumors, including those that emerge in the absence of overt inflammation. This knowledge has led to the development of anti-inflammatory concepts to treat and prevent cancer. In contrast, immunotherapies, in particular checkpoint inhibitors, representing the most significant progress in the therapy of several malignancies depend on the presence of a pro-inflammatory hot environment. Here, we discuss pro- and anti-inflammatory concepts for the treatment of cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available